GlassScriptPhysician profile
Mckenna Abercrombie
NPI 1902366008
$5,708.85
in general payments reported to CMS, 2019-2025
26 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.20 · 2020: $18.15 · 2021: $47.51 · 2022: $125 · 2023: $407 · 2024: $2,610 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,271 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,270.89 |
| Education | $233.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $780.56 | 2020-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $694.47 | 2024-2025 | Tremfya |
| Pfizer INC. | $643.44 | 2023-2025 | |
| Genzyme Corporation | $476.13 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $397.39 | 2023-2025 | |
| Lilly USA, LLC | $353.69 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $315.42 | 2024-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $303.41 | 2024-2025 | |
| Ucb, INC. | $263.82 | 2024-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $256.28 | 2023-2025 | Zoryve |
| Amgen INC. | $194.88 | 2024-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $193.48 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $178.16 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $147.20 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $116.07 | 2025 | Anzupgo, Adbry, Spevigo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $89.44 | 2025 | Opzelura, Opzelura |
| Almirall LLC | $67.56 | 2024-2025 | Seysara, Klisyri |
| Botanix Sb INC | $44.46 | 2025 | Sofdra |
| Lnhc, INC | $34.83 | 2025 | Zelsuvmi |
| Smith+Nephew, INC. | $30.89 | 2025 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.61 | 2024 | Spevigo |
| Mayne Pharma Commercial LLC | $29.95 | 2025 | |
| Fidia Pharma USA INC. | $19.61 | 2024 | |
| Organon LLC | $18.65 | 2025 | |
| Mimedx Group, INC. | $14.25 | 2025 | |
| Novo Nordisk INC | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenna Abercrombie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.